Skip to content

Study · Not a test of the peptide alone · 2024

4 results

Neuropathy of diabetes following initiation of a low-carbohydrate diet: Case report.

Sahyouni MJ, Acevedo LA, Rodriguez SC, Chiles JA, Pennings NJ

Obesity pillars14 Jun 2024Cited by 2 (Europe PMC)

PMID38983905 (opens in a new tab)PMCIDPMC11231748 (opens in a new tab)DOI10.1016/j.obpill.2024.100115 (opens in a new tab)PepBankPUB-38983905
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

IntroductionThis case study portrays an unusual case of treatment-induced neuropathy of diabetes (TIND) in a patient with uncontrolled type 2 diabetes (T2D) who achieved rapid improvement in glucose control primarily with dietary intervention. Initial presentation was 50-year-old white male with a long-standing history of obesity and a family history of T2D with a screening glucose level >500mg/dL by glucometer, HbA1c of 14.9%, and initial weight 213 lbs.MethodsThe initial intervention included a low-carbohydrate diet, metformin, and a continuous glucose monitor (CGM). Semaglutide was added after seven days.ResultsHis glycemia was within the target range within three weeks. Four weeks after initiation of therapy, he developed TIND symptoms consisting of burning, tightness, and numbness of bilateral feet along with 10/10 pain. At three months, his HbA1c dropped to 6.9% and his weight to 195 lbs. Treatment of his TIND reduced his pain from 10/10 to 2/10.ConclusionWhereas TIND is commonly associated with the use of insulin or sulfonylureas, this study adds evidence to the paucity of literature regarding TIND precipitated by dietary intervention.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a man with uncontrolled type 2 diabetes, a regimen of a low-carbohydrate diet, metformin and later semaglutide brought glycaemia within the target range within three weeks.

    In plain wordsIn one man with uncontrolled type 2 diabetes, a diet, metformin and semaglutide plan brought blood glucose into the target range within three weeks.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlycaemia within target range
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    His glycemia was within the target range within three weeks.
    3 context sentences
    Summary · context
    Initial presentation was 50-year-old white male with a long-standing history of obesity and a family history of T2D with a screening glucose level >500mg/dL by glucometer, HbA1c of 14.9%, and initial weight 213 lbs.
    Summary · context
    The initial intervention included a low-carbohydrate diet, metformin, and a continuous glucose monitor (CGM).
    Summary · context
    Semaglutide was added after seven days.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a man with uncontrolled type 2 diabetes, HbA1c dropped to 6.9% at three months on a regimen of a low-carbohydrate diet, metformin and semaglutide.

    In plain wordsIn one man with type 2 diabetes, HbA1c fell to 6.9% after three months of a diet, metformin and semaglutide plan.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c at three months
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c
    6.9%
    3 months

    Source sentences

    Summary
    At three months, his HbA1c dropped to 6.9% and his weight to 195 lbs.
    3 context sentences
    Summary · context
    Initial presentation was 50-year-old white male with a long-standing history of obesity and a family history of T2D with a screening glucose level >500mg/dL by glucometer, HbA1c of 14.9%, and initial weight 213 lbs.
    Summary · context
    The initial intervention included a low-carbohydrate diet, metformin, and a continuous glucose monitor (CGM).
    Summary · context
    Semaglutide was added after seven days.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a man with uncontrolled type 2 diabetes, weight fell to 195 lbs at three months on a regimen of a low-carbohydrate diet, metformin and semaglutide.

    In plain wordsIn one man with type 2 diabetes, weight fell to 195 lbs after three months of a diet, metformin and semaglutide plan.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight at three months
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight
    195 lbs
    3 months

    Source sentences

    Summary
    At three months, his HbA1c dropped to 6.9% and his weight to 195 lbs.
    3 context sentences
    Summary · context
    Initial presentation was 50-year-old white male with a long-standing history of obesity and a family history of T2D with a screening glucose level >500mg/dL by glucometer, HbA1c of 14.9%, and initial weight 213 lbs.
    Summary · context
    The initial intervention included a low-carbohydrate diet, metformin, and a continuous glucose monitor (CGM).
    Summary · context
    Semaglutide was added after seven days.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    A man with type 2 diabetes developed treatment-induced neuropathy of diabetes four weeks after starting a regimen of a low-carbohydrate diet, metformin and semaglutide.

    In plain wordsOne man with type 2 diabetes developed painful nerve symptoms four weeks after starting a diet, metformin and semaglutide plan.

    Peptide
    Semaglutide
    Outcome
    IncreaseTreatment-induced neuropathy of diabetes
    Study

    n = 1

    Outcome group
    Adverse events · Nervous system and cognition

    Source sentences

    Summary
    Four weeks after initiation of therapy, he developed TIND symptoms consisting of burning, tightness, and numbness of bilateral feet along with 10/10 pain.
    3 context sentences
    Summary · context
    Initial presentation was 50-year-old white male with a long-standing history of obesity and a family history of T2D with a screening glucose level >500mg/dL by glucometer, HbA1c of 14.9%, and initial weight 213 lbs.
    Summary · context
    The initial intervention included a low-carbohydrate diet, metformin, and a continuous glucose monitor (CGM).
    Summary · context
    Semaglutide was added after seven days.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.